Julien Hadoux

19PUBLICATIONS
87CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsHaematological tumoursOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jul 13, 2026
Hepatic arterial embolization procedures in neuroendocrine tumors with carcinoid heart disease: a retrospective single-center study on safety and feasibility.

|Aug 19, 2025
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.

Rossella Elisei, Lori J Wirth, Jaume Capdevila

|Nov 25, 2024
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET).

Thomas Walter, Thierry Lecomte, Julien Hadoux

|Aug 02, 2024
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.

Lori J Wirth, Marcia S Brose, Vivek Subbiah

|Jun 10, 2024
Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group.

Benjamin Chevalier, Delphine Bonnet, Come Lepage

|Jan 11, 2024
Intraoperative Parathyroid Gland Identification Using Autofluorescence Imaging in Thyroid Cancer Surgery with Central Neck Dissection: Impact on Post-Operative Hypocalcemia.

Joanne Guerlain, Ingrid Breuskin, Muriel Abbaci

Pageof 4

Frequent Collaborators

3 joint publications

Dana M Hartl

2 joint publications

Antoine Italiano

2 joint publications

Arnaud Jannin

2 joint publications

Benjamin Besse